Targeted Therapy for Colon Cancer: Current Status
Introduction
Colorectal cancer is the third leading cause of cancer-related deaths in the United States, with over 50,000 deaths annually. Targeted therapy is a type of cancer treatment that uses drugs or other substances to specifically target cancer cells, without harming healthy cells. Targeted therapy has been shown to be effective in treating certain types of colon cancer, and is now considered a standard of care for these patients.
How Targeted Therapy Works
Targeted therapy drugs work by blocking the growth and spread of cancer cells. They do this by targeting specific molecules or proteins that are involved in the growth of cancer cells. By blocking these molecules or proteins, targeted therapy drugs can stop cancer cells from growing and dividing.
Types of Targeted Therapy
There are a number of different types of targeted therapy drugs that are used to treat colon cancer. These drugs can be divided into two main categories:
- Monoclonal antibodies: These drugs are designed to bind to specific proteins on the surface of cancer cells. By binding to these proteins, monoclonal antibodies can block the proteins from interacting with other molecules, which can stop cancer cells from growing and dividing.
- Small molecule inhibitors: These drugs are designed to bind to specific proteins inside cancer cells. By binding to these proteins, small molecule inhibitors can block the proteins from functioning, which can stop cancer cells from growing and dividing.
Current Status of Targeted Therapy for Colon Cancer
Targeted therapy has been shown to be effective in treating certain types of colon cancer, including:
- Colorectal cancer with KRAS mutations: KRAS is a gene that is involved in the growth of cancer cells. Mutations in KRAS can lead to the development of colon cancer. Targeted therapy drugs that block KRAS have been shown to be effective in treating colon cancer with KRAS mutations.
- Colorectal cancer with BRAF mutations: BRAF is another gene that is involved in the growth of cancer cells. Mutations in BRAF can lead to the development of colon cancer. Targeted therapy drugs that block BRAF have been shown to be effective in treating colon cancer with BRAF mutations.
- Colorectal cancer with HER2 overexpression: HER2 is a protein that is involved in the growth of cancer cells. Overexpression of HER2 can lead to the development of colon cancer. Targeted therapy drugs that block HER2 have been shown to be effective in treating colon cancer with HER2 overexpression.
Benefits of Targeted Therapy
Targeted therapy has a number of benefits over traditional chemotherapy drugs, including:
- Increased effectiveness: Targeted therapy drugs are more effective than traditional chemotherapy drugs at treating certain types of colon cancer.
- Reduced side effects: Targeted therapy drugs have fewer side effects than traditional chemotherapy drugs.
- Improved quality of life: Targeted therapy drugs can improve the quality of life for patients with colon cancer by reducing side effects and improving their overall health.
Conclusion
Targeted therapy is a promising new treatment option for patients with colon cancer. Targeted therapy drugs have been shown to be effective in treating certain types of colon cancer, and have fewer side effects than traditional chemotherapy drugs. Targeted therapy is now considered a standard of care for patients with colon cancer who have certain genetic mutations.
Secondary Keywords
- Colon cancer
- Targeted therapy
- KRAS mutations
- BRAF mutations
- HER2 overexpression
